Cleveland Biolabs (CBLI) 3.24 $CBLI
Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents
Marketwired - Wed Feb 11, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the issuance of several new patents for entolimod in the U.S. and other countries, further strengthening its patent position.
CBLI: 3.24 (+0.05)
Cleveland BioLabs Announces Annual Meeting
Marketwired - Tue Feb 10, 6:01AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will hold its 2015 Annual Meeting of Stockholders on April 14, 2015 in Buffalo, NY for stockholders of record as of March 5, 2015. The Company will distribute proxy materials to all eligible stockholders.
CBLI: 3.24 (+0.05)
Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
Marketwired - Thu Feb 05, 6:31AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2015 BIO CEO & Investor Conference, February 9-10, in New York, NY.
CBLI: 3.24 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 11:44AM CST
CALX: 8.65 (-0.03), NES: 3.52 (+0.13), RVP: 5.14 (-0.42), RL: 135.20 (-0.60), SR: 1.25 (+0.08), MWA: 9.19 (+0.09), OHGI: 1.82 (-0.12), GENE: 8.04 (+1.90), CALI: 1.35 (+0.06), WPRT: 6.06 (+0.26), RSYS: 2.15 (+0.05), EGLT: 10.60 (+0.58), PACB: 6.96 (-0.06), ACHN: 10.89 (-0.20), BBSI: 39.78 (+0.84), AVEO: 0.84 (-0.06), CBLI: 3.24 (+0.05), ENG: 1.85 (-0.06), PLNR: 6.63 (-0.07)
Cleveland BioLabs Announces $4.2 Million Financing
Marketwired - Wed Feb 04, 8:06AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into definitive agreements with two institutional investors to purchase a total of $4.2 million of equity securities of the Company. The closing of the offering is expected to take place on or about February 6, 2015, subject to the satisfaction of customary closing conditions.
CBLI: 3.24 (+0.05), LTS: 3.92 (-0.02)
Cleveland BioLabs Announces Oncology Clinical Development Update for Entolimod
Marketwired - Thu Jan 29, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced updates on oncology clinical development of entolimod (previously known as CBLB502).
CBLI: 3.24 (+0.05)
Cleveland Bio down after reverse split
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 11:00AM CST
CBLI: 3.24 (+0.05)
Cleveland BioLabs Announces Board Appointment
Marketwired - Wed Jan 28, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Elena Kasimova of BioProcess Capital Partners to the Company's Board of Directors. Ms. Kasimova was appointed pursuant to a Rights Agreement with Dr. Mikhail Mogutov, which was entered into in connection with a private sale of securities to Dr. Mogutov in June 2014. As a result of the June 2014 sale, Dr. Mogutov is a holder of approximately 9% of CBLI's outstanding shares of common stock.
CBLI: 3.24 (+0.05)
Cleveland BioLabs Announces Results of Special Meeting of Stockholders and Reverse Stock Split
Marketwired - Tue Jan 27, 3:30PM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that at a special meeting of stockholders held on January 27, 2015, stockholders authorized the Company's Board of Directors to effect a reverse stock split of the Company's common stock at a ratio in the range of 1:2 to 1:20.
CBLI: 3.24 (+0.05)
Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod (CBLB502) as a Medical Radiation Countermeasure
Marketwired - Mon Jan 12, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company received notice that the proposal application to support further development of entolimod as a medical radiation countermeasure has been recommended for funding subject to negotiations by the Department of Defense (DoD) office of Congressionally Directed Medical Research Programs (CDMRP). This award is subject to successful negotiations and availability of funds.
CBLI: 3.24 (+0.05)
Cleveland BioLabs and Incuron Announce Updates on Clinical Progress With Curaxin CBL0137
Marketwired - Tue Jan 06, 6:31AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced updates on clinical progress with lead oncology program, Curaxin CBL0137.
CBLI: 3.24 (+0.05)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4psrtz/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Gamida Cell - Piramal Enterprises - Aeolus - Cleveland BioLabs - Soligenix - NeoStem - Pluristem - Cumberland - Cellerant - Humanetics - Meabco - ActoKine - Priaxon - ProCertus BioPharm - Angion Biomedica - Onconova - Avaxia Biologics - Bolder Biotechnology - Stemedica Cell Technologies - Biothera - Terapio - Neumedicines - RxBio For more information visit http://www.researchandmarkets.com/research/4psrtz/radiation
CBLI: 3.24 (+0.05)
Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer
ACCESSWIRE - Thu Nov 13, 9:50AM CST
WHITEFISH, MT / ACCESSWIRE / November 13, 2014 / The biotechnology industry has significantly outperformed the general market for some time now. So far this year, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has jumped nearly 30% compared to a nearly 10% return for the S&P 500 SPDR ETF (NYSE: SPY). Investors concerned about the industry's lofty valuation may want to take a look at some smaller diversified players in the space.
SPY: 209.78 (+0.86), AZN: 69.96 (+0.20), IBB: 323.46 (+3.04), CBLI: 3.24 (+0.05)
Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Marketwired - Thu Nov 13, 9:22AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies in Oncotarget describing the preclinical efficacy of Curaxin CBL0137 as a single agent and in combination with the current standard-of-care therapy, gemcitabine, against different models of pancreatic ductal adenocarcinoma (PDA), including models of gemcitabine-resistant tumors. The reported studies were conducted by scientists at Roswell Park, SUNY Downstate Medical Center and Buffalo Biolabs, LLC.
CBLI: 3.24 (+0.05)
Cleveland BioLabs' (CBLI) CEO Yakov Kogan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 2:10PM CST
CBLI: 3.24 (+0.05)
Cleveland BioLabs EPS of $0.07
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:13AM CST
CBLI: 3.24 (+0.05)
Cleveland BioLabs Reports Third Quarter 2014 Financial Results and Development Progress
Marketwired - Wed Nov 05, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2014.
CBLI: 3.24 (+0.05)
Cleveland BioLabs to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Wednesday, November 5, 2014
ACCESSWIRE - Tue Nov 04, 4:09PM CST
BUFFALO, NY / ACCESSWIRE / November 4, 2014 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Wednesday, November 5, 2014 at 10:00 AM Eastern Time.
CBLI: 3.24 (+0.05)
Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5
Marketwired - Tue Oct 28, 7:02AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2014, it will report its financial results for the third quarter ended September 30, 2014, and will host a conference call at 10:00 a.m. ET.
CBLI: 3.24 (+0.05)
Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents
Marketwired - Wed Feb 11, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the issuance of several new patents for entolimod in the U.S. and other countries, further strengthening its patent position.
CBLI: 3.24 (+0.05)
Cleveland BioLabs Announces Annual Meeting
Marketwired - Tue Feb 10, 6:01AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will hold its 2015 Annual Meeting of Stockholders on April 14, 2015 in Buffalo, NY for stockholders of record as of March 5, 2015. The Company will distribute proxy materials to all eligible stockholders.
CBLI: 3.24 (+0.05)
Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
Marketwired - Thu Feb 05, 6:31AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2015 BIO CEO & Investor Conference, February 9-10, in New York, NY.
CBLI: 3.24 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 11:44AM CST
CALX: 8.65 (-0.03), NES: 3.52 (+0.13), RVP: 5.14 (-0.42), RL: 135.20 (-0.60), SR: 1.25 (+0.08), MWA: 9.19 (+0.09), OHGI: 1.82 (-0.12), GENE: 8.04 (+1.90), CALI: 1.35 (+0.06), WPRT: 6.06 (+0.26), RSYS: 2.15 (+0.05), EGLT: 10.60 (+0.58), PACB: 6.96 (-0.06), ACHN: 10.89 (-0.20), BBSI: 39.78 (+0.84), AVEO: 0.84 (-0.06), CBLI: 3.24 (+0.05), ENG: 1.85 (-0.06), PLNR: 6.63 (-0.07)
Cleveland BioLabs Announces $4.2 Million Financing
Marketwired - Wed Feb 04, 8:06AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into definitive agreements with two institutional investors to purchase a total of $4.2 million of equity securities of the Company. The closing of the offering is expected to take place on or about February 6, 2015, subject to the satisfaction of customary closing conditions.
CBLI: 3.24 (+0.05), LTS: 3.92 (-0.02)
Cleveland BioLabs Announces Oncology Clinical Development Update for Entolimod
Marketwired - Thu Jan 29, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced updates on oncology clinical development of entolimod (previously known as CBLB502).
CBLI: 3.24 (+0.05)
Cleveland Bio down after reverse split
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 11:00AM CST
CBLI: 3.24 (+0.05)
Cleveland BioLabs Announces Board Appointment
Marketwired - Wed Jan 28, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Elena Kasimova of BioProcess Capital Partners to the Company's Board of Directors. Ms. Kasimova was appointed pursuant to a Rights Agreement with Dr. Mikhail Mogutov, which was entered into in connection with a private sale of securities to Dr. Mogutov in June 2014. As a result of the June 2014 sale, Dr. Mogutov is a holder of approximately 9% of CBLI's outstanding shares of common stock.
CBLI: 3.24 (+0.05)
Cleveland BioLabs Announces Results of Special Meeting of Stockholders and Reverse Stock Split
Marketwired - Tue Jan 27, 3:30PM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that at a special meeting of stockholders held on January 27, 2015, stockholders authorized the Company's Board of Directors to effect a reverse stock split of the Company's common stock at a ratio in the range of 1:2 to 1:20.
CBLI: 3.24 (+0.05)
Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod (CBLB502) as a Medical Radiation Countermeasure
Marketwired - Mon Jan 12, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company received notice that the proposal application to support further development of entolimod as a medical radiation countermeasure has been recommended for funding subject to negotiations by the Department of Defense (DoD) office of Congressionally Directed Medical Research Programs (CDMRP). This award is subject to successful negotiations and availability of funds.
CBLI: 3.24 (+0.05)
Cleveland BioLabs and Incuron Announce Updates on Clinical Progress With Curaxin CBL0137
Marketwired - Tue Jan 06, 6:31AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced updates on clinical progress with lead oncology program, Curaxin CBL0137.
CBLI: 3.24 (+0.05)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4psrtz/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Gamida Cell - Piramal Enterprises - Aeolus - Cleveland BioLabs - Soligenix - NeoStem - Pluristem - Cumberland - Cellerant - Humanetics - Meabco - ActoKine - Priaxon - ProCertus BioPharm - Angion Biomedica - Onconova - Avaxia Biologics - Bolder Biotechnology - Stemedica Cell Technologies - Biothera - Terapio - Neumedicines - RxBio For more information visit http://www.researchandmarkets.com/research/4psrtz/radiation
CBLI: 3.24 (+0.05)
Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer
ACCESSWIRE - Thu Nov 13, 9:50AM CST
WHITEFISH, MT / ACCESSWIRE / November 13, 2014 / The biotechnology industry has significantly outperformed the general market for some time now. So far this year, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has jumped nearly 30% compared to a nearly 10% return for the S&P 500 SPDR ETF (NYSE: SPY). Investors concerned about the industry's lofty valuation may want to take a look at some smaller diversified players in the space.
SPY: 209.78 (+0.86), AZN: 69.96 (+0.20), IBB: 323.46 (+3.04), CBLI: 3.24 (+0.05)
Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Marketwired - Thu Nov 13, 9:22AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies in Oncotarget describing the preclinical efficacy of Curaxin CBL0137 as a single agent and in combination with the current standard-of-care therapy, gemcitabine, against different models of pancreatic ductal adenocarcinoma (PDA), including models of gemcitabine-resistant tumors. The reported studies were conducted by scientists at Roswell Park, SUNY Downstate Medical Center and Buffalo Biolabs, LLC.
CBLI: 3.24 (+0.05)
Cleveland BioLabs' (CBLI) CEO Yakov Kogan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 2:10PM CST
CBLI: 3.24 (+0.05)
Cleveland BioLabs EPS of $0.07
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:13AM CST
CBLI: 3.24 (+0.05)
Cleveland BioLabs Reports Third Quarter 2014 Financial Results and Development Progress
Marketwired - Wed Nov 05, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2014.
CBLI: 3.24 (+0.05)
Cleveland BioLabs to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Wednesday, November 5, 2014
ACCESSWIRE - Tue Nov 04, 4:09PM CST
BUFFALO, NY / ACCESSWIRE / November 4, 2014 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Wednesday, November 5, 2014 at 10:00 AM Eastern Time.
CBLI: 3.24 (+0.05)
Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5
Marketwired - Tue Oct 28, 7:02AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2014, it will report its financial results for the third quarter ended September 30, 2014, and will host a conference call at 10:00 a.m. ET.
CBLI: 3.24 (+0.05)
